Contraindications

Certain conditions represent absolute contraindications for most research peptides. These include active pregnancy or breastfeeding (insufficient safety data for virtually all research peptides), active cancer or recent cancer history (many peptides promote angiogenesis or cell proliferation), and known hypersensitivity to the specific peptide or its excipients.

Relative contraindications — conditions where the risk-benefit ratio must be carefully assessed — include autoimmune conditions (immunomodulatory peptides may exacerbate autoimmune activity), bleeding disorders or anticoagulant therapy (some peptides affect platelet function or coagulation), and uncontrolled diabetes (GLP-1 agonists and other metabolic peptides require careful glucose monitoring).

Age-related considerations: most peptide research has been conducted in adults aged 18-65. Pediatric and elderly populations may metabolize peptides differently, and safety data in these groups is generally lacking.

Peptides that promote angiogenesis (new blood vessel formation) — such as BPC-157, TB-500, and growth hormone secretagogues — carry a theoretical risk of supporting tumor vascularization and growth. While no clinical studies have confirmed this risk, the biological mechanism is well-established.

Growth hormone secretagogues (GHRP-6, Ipamorelin, CJC-1295, MK-677) increase IGF-1 levels, which has been associated with increased cancer risk in epidemiological studies. Individuals with a personal or strong family history of cancer should exercise extreme caution.

GLP-1 receptor agonists carry a black box warning for thyroid C-cell tumors based on rodent studies. While human relevance is uncertain, these should be avoided in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Research peptides are not FDA-approved medications. Their safety profiles are based on limited clinical data, preclinical studies, and anecdotal community reports. Professional medical guidance provides critical safeguards.

A qualified healthcare provider can: review your medical history for contraindications, order baseline bloodwork to establish reference values, monitor for adverse effects through follow-up labs, identify potential drug interactions with your current medications, and provide emergency guidance if adverse events occur.

Baseline bloodwork before starting any peptide protocol typically includes: complete blood count (CBC), comprehensive metabolic panel (CMP), liver function (ALT, AST), kidney function (BUN, creatinine), fasting glucose, HbA1c, lipid panel, thyroid panel (TSH, free T4), and IGF-1 (for growth hormone secretagogues).

Peptides can interact with prescription medications through pharmacokinetic mechanisms (affecting absorption, distribution, metabolism, or excretion) or pharmacodynamic mechanisms (additive, synergistic, or opposing effects).

High-risk interaction categories include: GLP-1 agonists + insulin or oral hypoglycemics (additive hypoglycemia risk); GLP-1 agonists + oral medications (delayed gastric emptying can alter absorption timing); growth hormone peptides + diabetes medications (GH raises blood glucose); BPC-157 + anticoagulants (BPC-157 affects coagulation and vessel constriction); immunomodulatory peptides + immunosuppressants (unpredictable immune effects).

Always disclose all supplements, over-the-counter medications, and research compounds to your healthcare provider. Many interactions are not well-documented for research peptides, so conservative caution is warranted.

Cardiovascular disease: Some peptides affect blood pressure, heart rate, or fluid balance. Growth hormone secretagogues can cause fluid retention. BPC-157 affects blood vessel constriction and formation. Discuss with a cardiologist.

Liver or kidney disease: Peptides are metabolized hepatically and cleared renally. Impaired organ function can alter peptide pharmacokinetics, leading to accumulation or unpredictable effects. Dose adjustments may be necessary.

Endocrine disorders: Peptides that affect hormone signaling (GH secretagogues, GLP-1 agonists, melanocortin peptides) can interact with pre-existing endocrine conditions. Thyroid disorders, adrenal insufficiency, and sex hormone imbalances require careful evaluation.

Psychiatric conditions: Some peptides (particularly melanocortin agonists and certain nootropics) affect neurotransmitter signaling and can influence mood, anxiety, or compulsive behavior. Disclose any psychiatric history.

Pregnancy and breastfeeding: There is insufficient safety data for virtually all research peptides during pregnancy and lactation. This is an absolute contraindication.